The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.

Macalalad, Alexander R

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. [electronic resource] - Current medical research and opinion Mar 2015 - 537-45 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1473-4877

10.1185/03007995.2015.1008131 doi


Age Factors
Antineoplastic Agents--therapeutic use
Brentuximab Vedotin
Disease Management
Disease Progression
Hodgkin Disease--epidemiology
Humans
Immunoconjugates--therapeutic use
Ki-1 Antigen--metabolism
Lymphoma, Large-Cell, Anaplastic--epidemiology
Molecular Targeted Therapy--methods
Recurrence
Sex Factors
Treatment Outcome